Paroxysmal supraventricular tachycardia, referred to as “supraventricular tachycardia”, is one of the most common diseases in cardiology. Atrioventricular nodal tachycardia and atrioventricular tachycardia are the most common, with a predominance of young and middle-aged patients, as well as children and older adults. The symptoms of supraventricular tachycardia are mainly paroxysmal panic attacks with an accelerated heart rate (pulse), often 150-250 beats per minute, with sudden onset and stop, lasting from a few seconds, minutes to hours or even days, and some patients may have chest tightness and polyuria. The diagnosis can be confirmed by recording an ECG during an attack, but most ECGs are normally normal and easily missed, and some patients can be recorded as “pre-excited” on the ECG. Overall, supraventricular tachycardia is a benign type of arrhythmia. However, the frequency of episodes can be too fast, leading to blackouts, syncope and even sudden death (e.g., pre-excitation with atrial fibrillation); with increasing age, episodes can be accompanied by angina pectoris, heart failure, hypotension and even shock; long-term recurrent episodes can lead to cardiac enlargement, tachycardia and cardiomyopathy, and in some patients, atrial fibrillation. Drugs can control some of the symptoms of supraventricular tachycardia, but they cannot cure it, and long-term use also has side effects. Transcatheter radiofrequency ablation (RFCA) is a minimally invasive interventional procedure for the treatment of supraventricular tachycardia, which has the advantages of mature technology, high success rate, low recurrence rate and few complications.